Congestive Heart Failure: Diagnosis, Pathophysiology,

Therapy, and Implications for Respiratory Care

Michael S Figueroa MD and Jay I Peters MD FAARC

Introduction
Pathophysiology of Congestive Heart Failure
Evaluation of the Patient With Congestive Heart Failure
Therapy for Congestive Heart Failure
Pulmonary Complications of Congestive Heart Failure
Exacerbations of Heart Failure: Use of CPAP and NPPV
Summary

Congestive heart failure (CHF) is a common clinical disorder that results in pulmonary vascular
congestion and reduced cardiac output. CHF should be considered in the differential diagnosis of
any adult patient who presents with dyspnea and/or respiratory failure. The diagnosis of heart
failure is often determined by a careful history and physical examination and characteristic chest-
radiograph findings. The measurement of serum brain natriuretic peptide and echocardiography
have substantially improved the accuracy of diagnosis. Therapy for CHF is directed at restoring
normal cardiopulmonary physiology and reducing the hyperadrenergic state. The cornerstone of
treatment is a combination of an angiotensin-converting-enzyme inhibitor and slow titration of a
blocker. Patients with CHF are prone to pulmonary complications, including obstructive sleep
apnea, pulmonary edema, and pleural effusions. Continuous positive airway pressure and nonin-
vasive positive-pressure ventilation benefit patients in CHF exacerbations. Key words: heart failure,
diastolic dysfunction, systolic dysfunction, obstructive sleep apnea, Cheyne-Stokes respiration, respira-
tory failure, noninvasive ventilation. [Respir Care 2006;51(4):403– 412. © 2006 Daedalus Enterprises]

Introduction cardiac disorder that impairs the ventricle’s ability to fill

with or eject blood. Since there is no definitive diagnostic
Congestive heart failure (CHF) is a complex clinical test for heart failure, it remains a clinical diagnosis that is
syndrome that can result from any functional or structural largely based on a careful history and physical examina-
tion and supported by ancillary tests such as chest radio-
graph, electrocardiogram, and echocardiography. Heart
Michael S Figueroa MD and Jay I Peters MD FAARC are affiliated with
the Division of Pulmonary and Critical Care Medicine, The University of failure is a common disease, affecting approximately 5
Texas Health Science Center, San Antonio, Texas. million people in the United States, and it occurs predom-
inately in the elderly, with almost 80% of cases occurring
Michael S Figueroa MD presented a version of this paper at the 21st
in patients over the age of 65.1 The magnitude of the
annual New Horizons symposium at the 51st International Respiratory
Congress of the American Association for Respiratory Care, held De- problem cannot be precisely assessed, because reliable pop-
cember 3–6, 2005, in San Antonio, Texas. ulation-based data on the prevalence, incidence, and prog-
nosis are lacking. Nevertheless, several studies have found
Correspondence: Michael S Figueroa MD, Division of Pulmonary and
Critical Care Medicine, University of Texas Health Science Center, 7704
that CHF is associated with a 2-year mortality rate of
Merton Minter Boulevard, 111E, San Antonio TX 78229. E-mail: approximately 45–50%, which approaches that of many
[email protected]. malignancies.2 Moreover, from a societal perspective, car-

RESPIRATORY CARE  APRIL 2006 VOL 51 NO 4

403 RESPIRATORY CARE  APRIL 2006 VOL 51 N403
O 4
CONGESTIVE HEART FAILURE: DIAGNOSIS, PATHOPHYSIOLOGY, THERAPY, AND IMPLICATIONS FOR RESPIRATORY CARE

ing for patients with CHF accounts for 2–3% of the federal
health-care budget. The estimated direct and indirect cost
of CHF in the United States in 2005 was $27.9 billion.1
There are 2 mechanisms of reduced cardiac output and
heart failure: systolic dysfunction and diastolic dysfunc-
tion. The most common causes of systolic dysfunction
(defined by a left-ventricular ejection fraction of 50%)
are ischemic heart disease, idiopathic dilated cardiomyop-
athy, hypertension, and valvular heart disease. Diastolic
dysfunction (defined as dysfunction of left-ventricular fill-
ing with preserved systolic function) may occur in up to
40 –50% of patients with heart failure, it is more prevalent
in women, and it increases in frequency with each decade Fig. 1. Determinants of cardiac output.
of life. Diastolic dysfunction can occur in many of the
same conditions that lead to systolic dysfunction. The most standing the pathophysiologic consequences of heart fail-
common causes are hypertension, ischemic heart disease, ure and the potential treatments. Furthermore, an appreci-
hypertrophic cardiomyopathy, and restrictive cardiomyop- ation of cardiopulmonary interactions is important in our
athy. Many patients who have symptoms suggestive of understanding of heart failure. In the simplest terms, the
heart failure (shortness of breath, peripheral edema, par- heart can be viewed as a dynamic pump. It is not only
oxysmal nocturnal dyspnea) but also have preserved left- dependent on its inherent properties, but also on what is
ventricular function may not have diastolic dysfunction; pumped in and what it must pump against. The preload
instead, their symptoms are caused by other etiologies, characterizes the volume that the pump is given to send
such as lung disease, obesity, or occult coronary isch- forward, the contractility characterizes the pump, and the
emia.3 This article will review the pathophysiology, diag- afterload determines what the heart must work against.
nosis, and treatment of CHF, with specific discussion of The preload is often expressed as the end-diastolic pres-
the pulmonary manifestations and their treatment, includ- sure/volume of the left ventricle and is clinically assessed
ing noninvasive positive-pressure ventilation (NPPV) strat- by measuring the right atrial pressure. However, the pre-
egies. load is not only dependent on intravascular volume; it is
also influenced by any restriction to ventricular filling.
Pathophysiology of Congestive Heart Failure Since the heart resides in the thoracic cavity, an increased
positive pleural pressure (as seen with dynamic hyperin-
The syndrome of CHF arises as a consequence of an flation in chronic obstructive pulmonary disease or asthma)
abnormality in cardiac structure, function, rhythm, or con- can reduce right-atrial pressure (which equals central ve-
duction. In developed countries, ventricular dysfunction nous pressure minus pleural pressure) and thus reduce ven-
accounts for the majority of cases and results mainly from tricular filling. The cardiac pump is a muscle and will
myocardial infarction (systolic dysfunction), hypertension respond to the volume it is given with a determined output.
(diastolic and systolic dysfunction), or in many cases both. If volume increases, so will the amount pumped out in a
Degenerative valve disease, idiopathic cardiomyopathy, normal physiologic state, to a determined plateau; this
and alcoholic cardiomyopathy are also major causes of relationship is described by the Frank-Starling law (Figs. 2
heart failure. Heart failure often occurs in elderly patients and 3).5
who have multiple comorbid conditions (eg, angina, hy- A concept that is often poorly understood is the diastolic
pertension, diabetes, and chronic lung disease). Some com- function of the heart. Diastolic function is determined by
mon comorbidities such as renal dysfunction are multifac- 2 factors: the elasticity or distensibility of the left ventri-
torial (decreased perfusion or volume depletion from cle, which is a passive phenomenon, and the process of
overdiuresis), whereas others (eg, anemia, depression, dis- myocardial relaxation, which is an active process that re-
orders of breathing, and cachexia) are poorly understood.4 quires metabolic energy.6 Relaxation of the myocardium
CHF indicates not only an inability of the heart to main- occurs in early diastole, and the “untwisting” of the left
tain adequate oxygen delivery; it is also a systemic re- ventricle is an active process that produces a suction effect
sponse attempting to compensate for the inadequacy. The that augments left-ventricular filling. Loss of normal left-
determinants of cardiac output include heart rate and stroke ventricular distensibility or relaxation by either structural
volume (Fig. 1). The stroke volume is further determined changes (eg, left-ventricular hypertrophy) or functional
by the preload (the volume that enters the left ventricle), changes (eg, ischemia) impairs ventricular filling (preload).
contractility, and afterload (the impedance of the flow from The exercise intolerance seen with diastolic dysfunction
the left ventricle). These variables are important in under- largely results from the impairment of ventricular filling,

RESPIRATORY CARE  APRIL 2006 VOL 51 NO 4

404 RESPIRATORY CARE  APRIL 2006 VOL 51 N404
O 4
CONGESTIVE HEART FAILURE: DIAGNOSIS, PATHOPHYSIOLOGY, THERAPY, AND IMPLICATIONS FOR RESPIRATORY CARE

systolic function will maintain an ejection fraction of over

50 –55%. A previous myocardial infarction may result in
nonfunctioning myocardium that will impair contractility.
A recent concept is that ischemic myocardial tissue can be
nonfunctioning (hibernating) but revitalized by surgical or
medical therapy directed at ischemic heart disease.9 Other
depressants of myocardial systolic function include phar-
macologic agents (calcium-channel blockers), hypoxemia,
and severe acidosis.
The final determinant of stroke volume is afterload. In
basic terms, afterload is the load that the pump has to work
against, which is usually clinically estimated by the mean
arterial pressure. The normal cardiac output is relatively
insensitive to afterload up to 140 mm Hg. However, the
afterload represents not only the vascular resistance but
Fig. 2. The Frank-Starling law of the heart states that as the ven- also the wall tension and intrathoracic pressure that the
tricular volume increases and stretches the myocardial muscle
fibers, the stroke volume increases, up to its maximum capacity.
myocardium must work against. Together, these 3 vari-
After that point, increasing volume increases pulmonary capillary ables are impaired in the patient with CHF.5
pressure (and pulmonary congestion), without increasing the stroke The failing heart in CHF can be best evaluated with the
volume or cardiac output. The mechanism is the length-force re- above variables considered together. If cardiac output falls,
lationships of muscle contraction. either the heart rate or stroke volume must change in order
to maintain perfusion. If stroke volume cannot be main-
tained, then heart rate must increase to maintain cardiac
which elevates left-atrial pressure and pulmonary venous output. However, the pathophysiology behind CHF in-
pressure and causes pulmonary congestion.7 Additionally, cludes not only a structural abnormality; it also includes
inadequate cardiac output during exercise results in poor the cardiovascular response to poor perfusion with the
perfusion of skeletal muscles, especially the leg muscles activation of the neurohumoral system.10 Activation of the
and the accessory muscles of respiration.8 renin-angiotensin system attempts to increase preload by
The second variable of stroke volume is cardiac con- stimulating retention of salt and water, increasing vaso-
tractility, which represents the muscular pumping of the constriction (and, thus, afterload), and augmenting cardiac
heart and is commonly expressed as the ejection fraction. contractility. Initially, this response will suffice, but pro-
Based on autonomic input, the heart will respond to the longed activation results in loss of myocytes and maladap-
same preload with different stroke volumes, depending on tive changes in the surviving myocytes and the extracel-
inherent characteristics of the heart. A heart with normal lular matrix. The stressed myocardium undergoes
remodeling and dilation in response to the insult.11 This
process also has detrimental effects on the functioning of
the lungs, kidneys, muscles, blood vessels, and probably
other organs. Remodeling also results in additional cardiac
decompensation from complications, including mitral re-
gurgitation from valvular annulus stretching, and cardiac
arrhythmias from atrial remodeling.10
The respiratory care provider often becomes involved
with the CHF patient as the elevated end-diastolic pressure
leads to pulmonary edema and dyspnea. Patients’ presen-
tation can greatly differ, depending on the chronicity of the
disease. For instance, most patients experience dyspnea
when pulmonary-artery occlusion pressure exceeds 25 mm
Hg. However, the patient with longstanding CHF can tol-
erate filling pressure up to 40 mm Hg.12 The lung provides
multiple mechanisms to avoid the consequences of pul-
monary edema. Initially, as pressure increases, pulmonary
Fig. 3. This series of Frank-Starling curves demonstrates that at
any given preload (end-diastolic volume), increases in contractility
capillaries are recruited and increase capacitance to deal
will increase stroke volume (volume of blood ejected from the with the added volume.13 As pressure continues to in-
ventricle with each beat). crease, volume can be diverted from the alveoli to the

RESPIRATORY CARE  APRIL 2006 VOL 51 NO 4

405 RESPIRATORY CARE  APRIL 2006 VOL 51 N405
O 4
CONGESTIVE HEART FAILURE: DIAGNOSIS, PATHOPHYSIOLOGY, THERAPY, AND IMPLICATIONS FOR RESPIRATORY CARE

interstitium. At this point, by action of pressure gradients,

fluid will form in the interlobular septae and the perihilar
region. As noted above, chronic heart failure is associated
with increased venous capacitance and lymphatic drainage
of the lung. As a result, crackles are often absent, even in
the setting of elevated pulmonary capillary pressure. Con-
tinued sodium retention preferentially results in peripheral
edema and, ultimately, in the development of pleural ef-
fusions.14 With acute decompensation, the pulmonary-
capillary membrane may succumb to increased pressure,
with shearing of the capillary and release of fluid, protein,
and occasionally red blood cells into the alveoli.15 The
lungs’ response will include cough, to expel the fluid in
the alveoli. The long-term response to elevated pulmonary
venous pressure includes interstitial fibrosis with thicken-
ing of the alveolar membrane.12 Thus, severe, chronic heart
failure can result in interstitial fibrosis and a restrictive
lung disease. Fig. 4. This anteroposterior chest radiograph shows pulmonary
vascular congestion, typical of acute congestive heart failure.

Evaluation of the Patient With

Congestive Heart Failure patients with dyspnea, a chest radiograph is a useful first
test for differentiating patients with heart failure from pa-
The approach to the patient with suspected heart failure tients with primary pulmonary disease (Fig. 4). Radio-
includes a history and physical examination, chest radio- graphic findings suggestive of heart failure include car-
graph, and a series of diagnostic tests to assess both the diomegaly (cardiac-to-thoracic ratio above 50%),
acuity and severity. History alone is insufficient to make cephalization of blood vessels, increased interstitial mark-
the diagnosis of heart failure, but often provides clues to ings, and pleural effusions.18
the cause (myocardial infarction or uncontrolled hyperten- A constellation of characteristic signs, symptoms, and
sion), the precipitating event (noncompliance with diet or radiographic findings, as described above, often lead to the
medications), and the severity. The symptoms of heart diagnosis of CHF (Table 1). Patients with previous evi-
failure can be related to either the reduction of cardiac dence of heart disease, diabetes mellitus, hypertension, or
output (fatigue, weakness) or to excess fluid retention (dys- documented coronary-artery disease are at increased risk
pnea, orthopnea, and “cardiac wheezing”). With progres- for CHF, and one should always consider CHF in the
sion to right-heart failure there may be hepatic congestion differential diagnosis of acute respiratory failure in these
(with right upper-quadrant discomfort), early satiety, an- patients.19 Until recently, beyond direct functional assess-
orexia, and discomfort with bending. Fluid retention also ments of cardiac contractility, there were no laboratory
results in peripheral edema and occasionally in increasing tests to assist in the diagnosis of heart failure. Brain na-
abdominal girth secondary to ascites. Absence of dyspnea triuretic peptide is one of a family of neurohormones that
on exertion essentially rules out heart failure due to left- is produced by the ventricles in response to increased pres-
ventricular dysfunction.16 Pulmonary congestion (with sure and volume load. It works to counteract the effect of
crackles and wheezing) is predominant in acute or sub- the renin-angiotensin system by providing vasodilation,
acute disease. Although commonly taught as an absolute natriuresis, diuresis, and decreased smooth-muscle prolif-
finding in CHF, crackles are present in only 20% of pa- eration. It has become a valuable tool to assist in deter-
tients with chronic CHF. In addition, lower-extremity mining the etiology, prognosis, and maintenance therapy
edema presents in about 25% of patients younger than 70 for patients with CHF.20 Plasma concentrations of brain
years of age.17 natriuretic peptide are helpful in distinguishing dyspnea
The most reliable indicator of volume overload is the from cardiac causes (either left-ventricular dysfunction or
presence of elevated jugular venous pulsation (estimated cor pulmonale) versus from pulmonary causes (chronic
by distention of the jugular veins with the patient sitting at obstructive pulmonary disease, asthma, or pneumonia). A
45°), which correlates with elevated pulmonary-artery oc- cut-off value of 100 pg/mL diagnoses heart failure with
clusion pressure 80% of the time.18 Ventricular enlarge- a sensitivity of over 90% and a predictive accuracy of
ment can be estimated by precordial palpation, and an 83%.21 Reducing the cut-off point to 50 pg/mL increased
apical pulsation displaced laterally to the midclavicular the sensitivity to 97%, and a value below 50 pg/mL vir-
line is usually indicative of left-ventricular enlargement. In tually rules out heart failure as a cause of dyspnea. Most

RESPIRATORY CARE  APRIL 2006 VOL 51 NO 4

406 RESPIRATORY CARE  APRIL 2006 VOL 51 N406
O 4
CONGESTIVE HEART FAILURE: DIAGNOSIS, PATHOPHYSIOLOGY, THERAPY, AND IMPLICATIONS FOR RESPIRATORY CARE

Table 1. Modified Framingham Criteria for the Diagnosis of Table 2. New York Heart Association Classification of Congestive
Chronic Heart Failure* Heart Failure*

Major Criteria Stage/Degree Symptoms and Activity-Limitations

Neck-vein distention
I - None No symptoms from ordinary activities
Orthopnea or paroxysmal nocturnal dyspnea
II - Mild Comfortable at rest or during mild exertion
Crackles ( 10 cm above base of lung)
III - Moderate Symptomatic with any activity
Cardiomegaly on chest radiograph
IV - Severe Symptomatic at rest. Confined to bed or chair
S3 gallop
Central venous pressure 12 mm Hg *http://www.americanheart.org
Left ventricular dysfunction on echocardiogram
Weight loss 4.5 kg in response to CHF treatment
Acute pulmonary edema
Minor Criteria hibitors are recommended for all patients with heart failure
Bilateral ankle edema
with reduced systolic function. The main adverse effects
Night cough
of ACE inhibitors are cough (up to 20%), symptomatic
Dyspnea on exertion
Hepatomegaly hypotension, and renal dysfunction.
Pleural effusion blockers protect the heart from the harmful effects of
Tachycardia ( 120 beats/min) norepinephrine and epinephrine. blockers, when started
in low doses and slowly increased, further reduce mortal-
*Diagnosis of chronic heart failure (CHF) requires two of the major criteria or one of the
major plus two of the minor criteria.
ity when added to an ACE inhibitor. Intolerance to
blockers is uncommon and is usually due to bradycardia or
dizziness. blockers may worsen pulmonary function in
patients with obstructive lung disease, but most patients
patients with heart failure have values of over 400 pg/mL, tolerate cardio-selective blockers when carefully moni-
but caution is necessary because pulmonary emboli and tored. Consequently, the combination of an ACE inhibitor
other causes of cor pulmonale are associated with high and a blocker is now the cornerstone of treatment for
values of brain natriuretic peptide. heart failure.
Diuretics are essential in the relief of dyspnea and signs
Therapy for Congestive Heart Failure of sodium and water retention (peripheral edema or pleural
effusion). They are best used in the minimum dose needed
Understanding the pathophysiology of heart failure al- to maintain the “dry weight” in patients with symptomatic
lows one to achieve the goals of treatment, which are to heart failure.
relieve symptoms, avoid hospital admissions, and prolong
A nonpharmacologic method that has proven useful is
life. Treatment for CHF consists of a combination of phar-
the implantation of a biventricular pacing device to create
macologic and nonpharmacologic therapies. Much litera-
ventricular synchronization, in the hope of improving car-
ture and research has been published on medical manage-
diac output.24 Additionally, implantable cardioverter defi-
ment of CHF. The basic theories include termination of the
brillators reduce the risk of death in patients who have
renin-angiotensin system to prevent the long-term compli-
moderate-to-severe symptomatic heart failure and a re-
cations of the cascade. Treatment often focuses on a com-
bination of afterload-reduction with angiotensin-convert- duced ejection fraction despite maximum medical thera-
ing-enzyme (ACE) inhibitors, reduction of catecholamine py.25
surges with blockers, and preload-reduction with diuret- Clinical stratification of patients to determine the need
ics.10,18 Each modality presents difficulties for certain char- for intervention in chronic CHF has been based on the
acteristic patient types, and patients with diastolic dys- New York Heart Association (NYHA) classification sys-
function often develop dizziness or hypotension with tem, which separates patients based on the limitations
overdiuresis. Although clinical trials have shown signifi- they experience in performing certain activities (Table
cantly lower mortality with multiple interventions, the over- 2). An NYHA class I patient has almost no evidence of
all death rate from heart failure continues to rise, 22 which limitation in daily performance of activities, whereas an
reflects the avoidance of premature mortality from predis- NYHA class IV patient experiences severe symptoms
posing conditions (myocardial infarction and hypertension) even at rest. 26 This system also provides a yardstick for
that are only palliated, not cured, by advances in therapy. comparing treatment modalities in clinical research. The
ACE inhibitors reduce the production of angiotensin II remainder of this article will discuss specific respiratory
and exert a biologic effect that improves symptoms, re- interventions used in the management of patients with
duces hospitalizations, and prolongs survival.23 ACE in- acute and chronic CHF.

RESPIRATORY CARE  APRIL 2006 VOL 51 NO 4

407 RESPIRATORY CARE  APRIL 2006 VOL 51 N407
O 4
CONGESTIVE HEART FAILURE: DIAGNOSIS, PATHOPHYSIOLOGY, THERAPY, AND IMPLICATIONS FOR RESPIRATORY CARE

Pulmonary Complications of creased sympathetic stimulation from apnea, hypoxia,

Congestive Heart Failure arousals, and CO2 retention.41
Risk factors for CSR/CSA in CHF patients include a
Often the consequences of chronic CHF are overlooked, body mass index 35 kg/m2 and age 60 years.42 The
because the focus is on acute pharmacologic interventions. Framingham Heart Study discovered that, for reasons un-
In stable out-patients with chronic mild CHF, 40 –50% known, CSR/CSA is rarely found in women with CHF.43
have obstructive sleep apnea (OSA) and/or Cheyne-Stokes Similar to OSA patients, those with CSR/CSA rarely present
respiration/central sleep apnea (CSR/CSA).27,28 Further- with excessive daytime sleepiness.28 Interestingly, there is
more, CHF patients with CSR/CSA have higher mortality a subgroup of patients who start the sleep period with
than same-stage CHF patients.29 OSA creates multiple OSA, which progresses to CSR/CSA late in the sleep pe-
stresses to the cardiovascular system, further exacerbating riod. This could represent a failing heart with increasing
the failing myocardium. Unlike patients who have primary pulmonary pressure and edema leading to the activation of
OSA but do not have CHF, more than 50% of those who the oscillatory cycle of breathing and CSR/CSA.41
have both CHF and OSA are asymptomatic.30 Apnea is The treatment of both OSA and CSR/CSA has been
characterized by a cessation of flow, measured at the nose reviewed in multiple trials that attempted to elucidate long-
or mouth, due to central or obstructive events, for 10 term effects. Until recently, the majority of trials concern-
seconds. OSA is defined as more than 5 of these apnea ing the use of CPAP for sleep-disordered breathing and
events per hour.31 The apneic events lead to an increased CHF have been short in length (approximately 3 months)
negative intrathoracic pressure, from the normal level up and with few patients. The majority of studies have fo-
to – 80 mm Hg.32 This leads to decreased preload, in- cused on physiologic end points, as described above, and
creased afterload, and intraventricular septal shift to the few studies have looked at clinical responses.
left, with a cumulative effect of further decreasing cardiac The Epworth Sleepiness Scale is often used as a clinical
output.33 qualitative assessment of the amount of sleepiness a per-
Hypoxia is another consequence of obstructive events, son experiences, and has been validated by multiple stud-
with a responsive pulmonary vasoconstriction that usually ies,44 which showed improved physiologic outcomes, such
is not sustained during the day; however, repeated epi- as cardiac function and sympathetic stimulation. However,
sodes can lead to right-ventricular hypertrophy.34 Further- those improvements did not translate to a clinical change
more, secondary to either hypoxia or the change in in- in blood pressure, NYHA classification, or maximum ex-
trathoracic pressure, a sympathetic surge accompanies the ercise capacity. A recent randomized controlled trial by
apneic event, exacerbating the underlying cardiac dysfunc- Mansfield et al45 attempted to show clinical benefit from
tion.1 This often leads to the complications of secondary CPAP in CHF, comparing variables such as changes in
arterial hypertension.35 Epworth Sleepiness Scale, blood pressure, maximum
Multiple small trials on the physiologic effects of con- oxygen consumption (V̇O 2max), and change in NYHA clas-
tinuous positive airway pressure (CPAP) have shown im- sification. Only a minimal change in Epworth Sleepiness
proved hemodynamic variables. Takasaki et al were the Scale was found to be clinically important.45 Nevertheless,
first to demonstrate that CPAP decreases intrathoracic pres- the authors did note a significant change in quality-of-life
sure, sympathetic surge stimulation, and blood-pressure assessments. Studies of CPAP intervention in patients with
variability.36 Moreover, CPAP improves ejection fraction OSA and CHF are difficult because of ethical consider-
by 8 –10%, with clinical symptom improvement. These ations. A large comparative trial with nontreatment of pa-
improvements were reversed with the removal of CPAP tients who have known OSA/CHF, or the use of sham
after follow-up for 1 week.37–39 CPAP also decreases mi- CPAP, is ethically complex.46
tral regurgitation fraction, heart rate, and afterload.37 In contrast to OSA, CSR/CSA and CHF has been more
CSR/CSA commonly presents as a direct complication extensively studied, showing a clearer association as a
of CHF. CSR represents the oscillation of PaCO 2 above and consequence of the disease. Furthermore, there have been
below the level that causes apnea. The mechanism is thought limited data to support the treatment of CSR/CSA in pa-
to be the stretch of J receptors in the lung, secondary to tients with CHF. This allows randomizing patients to treat-
pulmonary edema, which leads to initial hyperventilation. ment and nontreatment groups without ethical dilemmas.
An apneic period follows after CO2 reaches a threshold The respiratory drive consists of a balance of the control of
level, only to be followed by a period of hyperventilation peripheral and central chemoreceptors to changes in PCO2 ,
to compensate for the rising CO2. This cycle then repeats PO2, and blood pH.47
itself.40 In contrast to OSA, these apneas are secondary to Javaheri found that patients with CSR/CSA and CHF
increased ventilatory drive, as opposed to the effort in have an increased response to changes in CO2, which trans-
OSA to terminate the apnea.41 Nonetheless, CSR/CSA has lates to an overshoot in hyperventilation in patients who
similar hemodynamic consequences, secondary to in- experience apnea events.48 This accelerated respiratory

RESPIRATORY CARE  APRIL 2006 VOL 51 NO 4

408 RESPIRATORY CARE  APRIL 2006 VOL 51 N408
O 4
CONGESTIVE HEART FAILURE: DIAGNOSIS, PATHOPHYSIOLOGY, THERAPY, AND IMPLICATIONS FOR RESPIRATORY CARE

drive leads to a fall below the apneic threshold, which tion improves physiologic variables in both groups, but no
creates a cessation of breathing, a rise in CO2, and repe- trials in OSA have shown a mortality benefit, and its use
tition of the cycle. in CSR/CSA has not been proven beneficial.55
Nocturnal oxygen therapy is effective in patients who Patients with chronic CHF have decreased lung volume,
have CSR/CSA and CHF. Hanly et al, in a one-night study, decreased compliance, increased airway-closing pressure,
discovered that nocturnal oxygen improved oxygenation increased work of breathing, and greater oxygen consump-
and sleep architecture and decreased sleep-disordered tion.57 These pathological effects lead to the progression
breathing.49 Javaheri et al found that nasally administered and worsening of an already stressed system. Diffusion
oxygen, titrated up from 2 L/min to 4 L/min (based on capacity is also altered by CHF, but the extent of the
desaturation below 90%) decreased the incidence of CSA.50 change in diffusion capacity depends on the timing of the
Nocturnal oxygen decreases the incidence of sympathetic disease. Acute CHF usually presents with an increased
stimulation, which is a major determinant of poor prog- diffusion capacity secondary to intra-alveolar red blood
nosis in CHF.51,52 Multiple mechanisms have been hy- cells, which increase the uptake of carbon monoxide. In
pothesized to explain the effect of oxygen on CSR/CSA. contrast, patients with chronic CHF present with decreased
Administration of oxygen increases PCO2 by decreasing diffusion capacity and a restrictive lung defect, which is
tidal volume and is hypothesized to increase ventilation- probably from chronic interstitial edema and the resulting
perfusion mismatch.53,54 This rise in CO2 allows a wider interstitial fibrosis.58 Furthermore, this change in pulmo-
variation between the daytime CO2 and apneic threshold, nary mechanics is not reversed in patients who undergo
which decreases sleep-disordered breathing. cardiac transplantation.59 Pulmonary rehabilitation im-
As with OSA, the use of CPAP for CSR/CSA has mul- proves quality of life and exercise capacity in patients with
tiple physiologic effects. The majority of clinical trials chronic heart failure.
have been limited to small groups of patients and short
duration, and with varied results. However, a recent large Exacerbations of Heart Failure:
randomized controlled trial (the CANPAP trial), which Use of CPAP and NPPV
included 258 patients followed over a mean of 2 years,
provided the first long-term-follow-up data. The patients Acute pulmonary edema with respiratory distress is a
were predominantly older, white, and male, and had isch- common presentation to the hospital. The RT often be-
emic cardiomyopathy and an average ejection fraction of comes involved in NPPV, to prevent the need for intuba-
24%. Two thirds of the patients were in NYHA class II, tion. The rationale for using CPAP and NPPV in acute
and the rest were in NYHA class III or IV. Consistent with pulmonary edema is that positive pressure may limit the
previous trials, early analysis showed an improvement in decrease in functional residual capacity, improve respira-
the occurrence of central apnea, increases in mean oxygen tory mechanics and oxygenation, and decrease left-ven-
saturation, improved ejection fraction, and suppression of tricular preload and afterload. Theoretically, NPPV could
plasma catecholamine levels. However, the primary out- improve hypercarbia, with a greater decrease in work of
comes (death and cardiac transplantation) did not differ breathing.60 The patients who will most benefit from NPPV
between the 2 groups with the use of CPAP. Furthermore, are probably those presenting to the emergency room and
no difference was observed in morbidity measured by qual- who have a narrow time-window for intervention. The
ity-of-life assessment and hospitalization.55 These out- skill of the RT is critical in improving synchrony between
comes may reflect the difficulty in changing outcomes for the patient and the NPPV device.
patients who have a poor prognosis with CHF at this stage. Pang et al performed the first meta-analysis concerning
Only one prior study reported a mortality benefit with the the use of positive-pressure airway support. They found a
use of CPAP, and greater use of blockers in the treat- lower rate of intubation and a trend toward lower mortality
ment group may have accounted for the difference.56 By with CPAP.61 Later studies, however, failed to show a
decreasing sympathetic surge, CPAP may have provided a clear mortality benefit.62– 64 One of the early randomized
nonpharmacologic benefit that vanished with the increased controlled trials, by Mehta et al, raised the concern that
use of blockade in the CANPAP trial. It remains spec- NPPV might increase the rate of myocardial infarction,
ulative whether patients who have CSR/CSA and are in- compared to CPAP.65 However, the randomization of pa-
tolerant of blockers should be treated with CPAP. tients differed with the NPPV patients, such that there was
Sleep-disordered breathing occurs in approximately half a difference in the number of patients with chest pain
of patients who have chronic CHF, and the physiologic (71% vs 31%), and several patients in the NPPV group had
consequences are detrimental to the struggling cardiovas- evidence of evolving myocardial infarct at the time of
cular system. The respiratory therapist (RT) becomes in- randomization. NPPV (at 15/5 cm H2O) more rapidly im-
volved in providing means of support for patients who proved dyspnea, arterial blood gases, and vital signs than
have both OSA and CSR/CSA. Positive-pressure ventila- did CPAP (at 10 cm H2O).

RESPIRATORY CARE  APRIL 2006 VOL 51 NO 4

409 RESPIRATORY CARE  APRIL 2006 VOL 51 N409
O 4
CONGESTIVE HEART FAILURE: DIAGNOSIS, PATHOPHYSIOLOGY, THERAPY, AND IMPLICATIONS FOR RESPIRATORY CARE

Recently, a large randomized multicenter controlled trial ACKNOWLEDGMENTS

(n 130) by Nava et al compared NPPV to conventional Thanks to Stephanie M Levine MD, University of Texas Health Science
therapy (oxygen and pharmacologic intervention) in an Center at San Antonio, for editing assistance.
emergency-department setting.66 Using a portable ventila-
tor (PV102, Breas Medical, Mö lnlycke, Sweden) and full REFERENCES
face mask, a standardized protocol titrated the inspiratory
1. Nadar S, Prasad N, Taylor RS, Lip GY. Positive pressure ventilation
pressure to the maximum tolerated, and expiratory pres- in the management of acute and chronic cardiac failure: a systematic
sure to a rise in oxygen saturation (initial settings 10/5 cm review and meta-analysis. Int J Cardiol 2005;99(2):171–185.
H2O, average final settings 14.5/6.1 cm H2O). Compared 2. Khand A, Gemmel I, Clark AL, Cleland JG. Is the prognosis of heart
to standard medical treatment, NPPV significantly im- failure improving? J Am Coll Cardiol 2000;36(7):2284–2286.
3. Caruana L, Petrie MC, Davie AP, McMurray JJ. Do patients with
proved the respiratory rate, dyspnea score, and ratio of
suspected heart failure and preserved left ventricular systolic func-
PaO2 to fraction of inspired oxygen; however, there was no tion suffer from “diastolic heart failure” or from misdiagnosis? A
significant reduction in hospital mortality or need for in- prospective descriptive study. BMJ 2000;321(7255):215–218.
tubation. In a subgroup analysis of hypercapnic patients, 4. McMurray JJ, Pfeffer MA. Heart failure. Lancet 2005;365(9474):
NPPV improved PaCO2 significantly faster than did medi- 1877–1889.
cal therapy, and significantly reduced the intubation rate. 5. Brausnwald E. Disorders of the heart: normal and abnormal myo-
cardial function. In: Fauci AS, editor. Harrison’s principles of inter-
Adverse events, including myocardial infarction, were nal medicine, 14th ed. New York: McGraw-Hill; 1998: 1278–1286.
evenly distributed between the groups. 6. Aurigemma GP, Gaasch WH. Clinical practice: diastolic heart fail-
The RT must be aware of and communicate the com- ure. N Engl J Med 2004;351(11):1097–1105.
mon contraindications for CPAP and NPPV in the acute 7. Kitzman DW. Exercise intolerance. Prog Cardiovasc Dis 2005;47(6):
367–379.
setting, including inability to cooperate, inability to protect
8. Mancini DM. Pulmonary factors limiting exercise capacity in pa-
the airway, inability to clear secretions, high risk for as- tients with heart failure. Prog Cardiovasc Dis 1995;37(6):347–370.
piration, and cardiovascular instability. Moreover, clini- 9. Choudhury L, Gheorghiade M, Bonow RO. Coronary artery disease
cally the most critical factor is setting an end point for the in patients with heart failure and preserved systolic function. Am J
determination of the need for invasive ventilation, thereby Cardiol 2002;89(6):719–722.
10. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348(20):
preventing an extended NPPV trial that could have car-
2007–2018.
diovascular consequences. 11. Eichhorn EJ, Bristow MR. Medical therapy can improve the biolog-
ical properties of the chronically failing heart: a new era in the
Summary treatment of heart failure. Circulation 1996;94(9):2285–2296.
12. Gehlbach BK, Geppert E. The pulmonary manifestations of left heart
failure. Chest 2004;125(2):669–682.
Chronic heart failure is a complex cardiac condition that
13. West JB, Dollery CT, Naimark A. Distribution of blood flow in
encompasses several etiologies and comorbidities. It arises isolated lung: relation to vascular and alveolar pressures. J Appl
in the differential diagnosis in all adult patients who present Physiol 1964;19:713–724.
with dyspnea and/or respiratory failure. Definitive diag- 14. Malik A, Vogel SM, Minshall RD, et al. Pulmonary circulation and
nosis is established by a careful history and physical ex- regulation of fluid balance. In: Murray JF, Nadel JA, Mason RJ, et
al, editors. Textbook of respiratory medicine. Philadelphia: Saun-
amination and supportive laboratory data. A chest radio-
ders; 2000:19–54.
graph is useful in excluding a pulmonary etiology (eg, 15. Tsukimoto K, Mathieu-Costello O, Prediletto R, Elliott AR, West
pneumonia); however, a spiral computed-tomography an- JB. Ultrastructural appearances of pulmonary capillaries at high trans-
giogram may be required if the diagnosis of pulmonary mural pressures. J Appl Physiol 1991;71(2):573–582.
emboli is entertained. The availability of measuring serum 16. Davie AP, Francis CM, Caruana L, Sutherland GR, McMurray JJ.
Assessing diagnosis in heart failure: which features are any use?
brain natriuretic peptide and bedside echocardiography has
QJM 1997;90(5):335–339.
aided in our diagnostic precision. Therapy is primarily 17. Stevenson LW, Perloff JK. The limited reliability of physical signs
directed toward normalizing the underlying physiologic for estimating hemodynamics in chronic heart failure. JAMA 1989;
changes with ACE inhibitors and slow titration of block- 261(6):884–888.
ers. Diuretics are useful in reducing pulmonary vascular 18. Nohria A, Lewis E, Stevenson LW. Medical management of ad-
vanced heart failure. JAMA 2002;287(5):628–640.
congestion, which may reduce or resolve dyspnea. Exces-
19. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK.
sive therapy often reduces cardiac output or causes symp- Risk factors for congestive heart failure in US men and women:
tomatic hypotension, which occurs most commonly in pa- NHANES I epidemiologic follow-up study. Arch Intern Med 2001;
tients with diastolic dysfunction. Treatment of the 161(7):996–1002.
underlying etiology (silent ischemia or poorly controlled 20. de Denus S, Pharand C, Williamson DR. Brain natriuretic peptide in
the management of heart failure: the versatile neurohormone. Chest
hypertension) may halt or slow the progression of the dis-
2004;125(2):652–668.
ease. Treatment of comorbidities (eg, underlying pulmo- 21. Maisel A. B-type natriuretic peptide measurements in diagnosing
nary disease, cigarette abuse, or diabetes) is essential in congestive heart failure in the dyspneic emergency department pa-
optimizing patient outcome and improving quality of life. tient. Rev Cardiovasc Med 2002;3 Suppl 4:S10–S17.

RESPIRATORY CARE  APRIL 2006 VOL 51 NO 4

410 RESPIRATORY CARE  APRIL 2006 VOL 51 N410
O 4
CONGESTIVE HEART FAILURE: DIAGNOSIS, PATHOPHYSIOLOGY, THERAPY, AND IMPLICATIONS FOR RESPIRATORY CARE

22. Konstam MA. Progress in heart failure management? Lessons from effects of continuous positive airway pressure. Lancet 1991;
the real world. Circulation 2000;102(10):1076–1078. 338(8781):1480–1484.
23. The SOLVD Investigators. Effect of enalapril on mortality and the 40. Roux F, D’Ambrosio C, Mohsenin V. Sleep-related breathing dis-
development of heart failure in asymptomatic patients with reduced orders and cardiovascular disease. Am J Med 2000;108(5):396–402.
left ventricular ejection fractions. N Engl J Med 1992;327(10):685– 41. Bradley TD, Floras JS. Sleep apnea and heart failure: Part II: central
691. Erratum in: N Engl J Med 1992;327(24):1768. sleep apnea. Circulation 2003;107(13):1822–1826.
24. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh 42. Sin DD, Fitzgerald F, Parker JD, Newton G, Floras JS, Bradley TD.
E, et al; MIRACLE Study Group; Multicenter InSync Randomized Risk factors for central and obstructive sleep apnea in 450 men and
Clinical Evaluation. Cardiac resynchronization in chronic heart fail- women with congestive heart failure. Am J Respir Crit Care Med
ure. N Engl J Med 2002;346(24):1845–1853. 1999;160(4):1101–1106.
25. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et 43. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart
al; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Inves- failure: the Framingham Study. J Am Coll Cardiol 1993;22(4 Suppl
tigators. Amiodarone or an implantable cardioverter-defibrillator for A):6A–13A.
congestive heart failure. N Engl J Med 2005;352(3):225–237. Erra- 44. Johns MW. Daytime sleepiness, snoring, and obstructive sleep ap-
tum in: N Engl J Med 2005;352(20):2146. nea. The Epworth Sleepiness Scale. Chest 1993;103(1):30–36.
26. Grady KL, Dracup K, Kennedy G, Moser DK, Piano M, Stevenson 45. Mansfield DR, Gollogly NC, Kaye DM, Richardson M, Bergin P,
LW, Young JB. Team management of patients with heart failure: a Naughton MT. Controlled trial of continuous positive airway pres-
statement for healthcare professionals from The Cardiovascular Nurs- sure in obstructive sleep apnea and heart failure. Am J Respir Crit
ing Council of the American Heart Association. Circulation 2000; Care Med 2004;169(3):361–366.
102(19):2443–2456. 46. Leung RS, Tkacova R, Bradley TD. Obstructive sleep apnoea (let-
27. Blackshear JL, Kaplan J, Thompson RC, Safford RE, Atkinson EJ. ter). Lancet 1999;354(9185):1212–1213.
Nocturnal dyspnea and atrial fibrillation predict Cheyne-Stokes res- 47. Kohnlein T, Welte T, Tan LB, Elliott MW. Central sleep apnoea
pirations in patients with congestive heart failure. Arch Intern Med syndrome in patients with chronic heart disease: a critical review of
1995;155(12):1297–1302.
the current literature. Thorax 2002;57(6):547–554.
28. Javaheri S, Parker TJ, Liming JD, Corbett WS, Nishiyama H, Wexler
48. Javaheri S. A mechanism of central sleep apnea in patients with heart
L, Roselle GA. Sleep apnea in 81 ambulatory male patients with
failure. N Engl J Med 1999;341(13):949–954.
stable heart failure: types and their prevalences, consequences, and
49. Hanly PJ, Millar TW, Steljes DG, Baert R, Frais MA, Kryger MH.
presentations. Circulation 1998;97(21):2154–2159.
The effect of oxygen on respiration and sleep in patients with con-
29. Hanly PJ, Zuberi-Khokhar NS. Increased mortality associated with
gestive heart-failure. Ann Intern Med 1989;111(10):777–782.
Cheyne-Stokes respiration in patients with congestive heart failure.
50. Javaheri S, Ahmed M, Parker TJ, Brown CR. Effects of nasal O2 on
Am J Respir Crit Care Med 1996;153(1):272–276.
sleep-related disordered breathing in ambulatory patients with stable
30. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The
heart failure. Sleep 1999;22(8):1101–1106.
occurrence of sleep-disordered breathing among middle-aged adults.
51. Andreas S, Bingeli C, Mohacsi P, Luscher TF, Noll G. Nasal oxygen
N Engl J Med 1993;328(17):1230–1235.
31. The Report of an American Academy of Sleep Medicine Task Force. and muscle sympathetic nerve activity in heart failure. Chest 2003;
Sleep-related breathing disorders in adults: recommendation for syn- 123(2):366–371.
drome definition and measurement techniques in clinical research. 52. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS,
Sleep 1999;22(5):667–689. et al. Plasma norepinephrine as a guide to prognosis in patients with
32. Virolainen J, Ventila M, Turto H, Kupari M. Influence of negative chronic congestive heart failure. N Engl J Med 1984;311(13):819–
intrathoracic pressure on right atrial and systemic venous dynamics. 823.
Eur Heart J 1995;16(9):1293–1299. 53. Andreas S, Plock EH, Heindl S, Scholz KH. Nasal oxygen effects on
33. Buda AJ, Pinsky MR, Ingels NB Jr, Daughters GT 2nd, Stinson EB, arterial carbon dioxide pressure and heart rate in chronic heart fail-
Alderman EL. Effect of intrathoracic pressure on left ventricular ure. Am J Cardiol 1999;83(5):795–798.
performance. N Engl J Med 1979;301(9):453–459. 54. Javaheri S. Pembrey’s dream: the time has come for a long-term trial
34. Berman EJ, DiBenedetto RJ, Causey DE, Mims T, Conneff M, Good- of nocturnal supplemental nasal oxygen to treat central sleep apnea
man LS, Rollings RC. Right ventricular hypertrophy detected by in congestive heart failure. Chest 2003;123(2):322–325.
echocardiography in patients with newly diagnosed obstructive sleep 55. Bradley TD, Logan AG, Kimoff RJ, Series F, Morrison D, Ferguson
apnea. Chest 1991;100(2):347–350. K, et al; CANPAP Investigators. Continuous positive airway pres-
35. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural sure for central sleep apnea and heart failure. N Engl J Med 2005;
mechanisms in obstructive sleep apnea. J Clin Invest 1995;96(4): 353(19):2025–2033.
1897–1904. 56. Sin DD, Logan AG, Fitzgerald FS, Liu PP, Bradley TD. Effects of
36. Takasaki Y, Orr D, Popkin J, Rutherford R, Liu P, Bradley TD. continuous positive airway pressure on cardiovascular outcomes in
Effect of nasal continuous positive airway pressure on sleep apnea in heart failure patients with and without Cheyne-Stokes respiration.
congestive heart failure. Am Rev Respir Dis 1989;140(6):1578–1584. Circulation 2000;102(1):61–66.
37. Granton JT, Naughton MT, Benard DC, Liu PP, Goldstein RS, Brad- 57. Lenique F, Habis M, Lofaso F, Dubois-Rande JL, Harf A, Brochard
ley TD. CPAP improves inspiratory muscle strength in patients with L. Ventilatory and hemodynamic effects of continuous positive air-
heart failure and central sleep apnea. Am J Respir Crit Care Med way pressure in left heart failure. Am J Respir Crit Care Med 1997;
1996;153(1):277–282. 155(2):500–505.
38. Kaneko Y, Floras JS, Usui K, Plante J, Tkacova R, Kubo T, et al. 58. Wright RS, Levine MS, Bellamy PE, Simmons MS, Batra P, Steven-
Cardiovascular effects of continuous positive airway pressure in pa- son LW, et al. Ventilatory and diffusion abnormalities in potential
tients with heart failure and obstructive sleep apnea. N Engl J Med heart transplant recipients. Chest 1990;98(4):816–820.
2003;348(13):1233–1241. 59. Mettauer B, Lampert E, Charloux A, Zhao QM, Epailly E, Oswald
39. Malone S, Liu PP, Holloway R, Rutherford R, Xie A, Bradley TD. M, et al. Lung membrane diffusing capacity, heart failure, and heart
Obstructive sleep apnoea in patients with dilated cardiomyopathy: transplantation. Am J Cardiol 1999;83(1):62–67.

RESPIRATORY CARE  APRIL 2006 VOL 51 NO 4

411 RESPIRATORY CARE  APRIL 2006 VOL 51 N411
O 4
CONGESTIVE HEART FAILURE: DIAGNOSIS, PATHOPHYSIOLOGY, THERAPY, AND IMPLICATIONS FOR RESPIRATORY CARE

60. Liesching T, Kwok H, Hill NS. Acute applications of noninvasive 64. Takeda S, Takano T, Ogawa R. The effect of nasal continuous pos-
positive pressure ventilation. Chest 2003;124(2):699–713. itive airway pressure on plasma endothelin-1 concentrations in pa-
61. Pang D, Keenan SP, Cook DJ, Sibbald WJ. The effect of positive tients with severe cardiogenic pulmonary edema. Anesth Analg 1997;
pressure airway support on mortality and the need for intubation in 84(5):1091–1096.
cardiogenic pulmonary edema: a systematic review. Chest 1998; 65. Mehta S, Jay GD, Woolard RH, Hipona RA, Connolly EM, Cimini
114(4):1185–1192.
DM, et al. Randomized, prospective trial of bilevel versus continu-
62. Masip J, Betbese AJ, Paez J, Vecilla F, Canizares R, Padro J, et al.
ous positive airway pressure in acute pulmonary edema. Crit Care
Non-invasive pressure support ventilation versus conventional oxy-
Med 1997;25(4):620–628.
gen therapy in acute cardiogenic pulmonary oedema: a randomised
trial. Lancet 2000;356(9248):2126–2132. 66. Nava S, Carbone G, DiBattista N, Bellone A, Baiardi P, Cosentini
63. Philip-Joet FF, Paganelli FF, Dutau HL, Saadjian AY. Hemody- R,et al. Noninvasive ventilation in cardiogenic pulmonary edema: a
namic effects of bilevel nasal positive airway pressure ventilation in multicenter randomized trial.Am J Respir Crit Care Med 2003;
patients with heart failure. Respiration 1999;66(2):136–143. 168(12):1432–1437.

RESPIRATORY CARE  APRIL 2006 VOL 51 NO 4

412 RESPIRATORY CARE  APRIL 2006 VOL 51 N412
O 4